Clinical Trial Update: Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating bioequivalence of two tacrolimus 0.1% topical ointment formulations in patients with Atopic Dermatitis; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tacrolimus topical ointment (0.1% Formulation A) (tacrolimus)
• Tacrolimus topical ointment (0.1% Formulation B) (tacrolimus)

Snippet

Sponsor: Sun Pharmaceutical Industries, Inc. | Conditions: Atopic Dermatitis | Phase 1 | Status: COMPLETED